Date: 2016-01-26
Type of information: Nomination
Compound:
Company: DBV Technologies (France)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 26, 2016, DBV Technologies announced the appointment of Edward Jordan as Senior Vice President, Commercial Operations North America, effective January 4, 2016. Mr. Jordan will be responsible for leading the company’s commercial functions in North America. Mr. Jordan brings to DBV more than 20 years of commercial leadership and product launch experience in both prescription and over-the-counter (OTC) products. Prior to joining DBV, Mr. Jordan served as Senior Vice President, Commercial Operations at AMAG Pharmaceuticals, Inc. In that role, he oversaw commercialization strategies and execution for the global Hematology/Oncology business, which generated double-digit revenue growth during his tenure. In a prior role at Teva Pharmaceuticals, Mr. Jordan served as Head of Sales, Marketing, Training & Effectiveness, Women’s Health Care. He led a team of more than 250 individuals who drove steady growth in prescription, device and OTC sales, and successfully launched new products in both the prescription and OTC arenas. Earlier in his career, Mr. Jordan held a series of global development and leadership roles for the pharmaceutical business at Schering-Plough Corporation (now Merck). During his 17 years at Schering-Plough, he gained extensive allergy experience with multiple products at varying stages in their lifecycles. As Senior Director of International Operations, Mr. Jordan engineered enhancements to financial planning, promotional strategies, launch excellence and operational effectiveness, optimizing profitability and ensuring the consistent and effective deployment of global brands across countries. Mr. Jordan earned an MBA from Southern New Hampshire University, and dual Bachelor of Science degrees in finance and insurance from the University of Rhode Island.
Financial terms:
Latest news:
